Compare NVTS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVTS | MNKD |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2004 |
| Metric | NVTS | MNKD |
|---|---|---|
| Price | $8.12 | $5.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.92 | ★ $10.08 |
| AVG Volume (30 Days) | ★ 18.2M | 2.8M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | N/A | ★ 0.10 |
| Revenue | $56,598,000.00 | ★ $313,787,000.00 |
| Revenue This Year | N/A | $21.54 |
| Revenue Next Year | N/A | $22.21 |
| P/E Ratio | ★ N/A | $60.68 |
| Revenue Growth | N/A | ★ 17.43 |
| 52 Week Low | $1.52 | $3.38 |
| 52 Week High | $17.79 | $7.07 |
| Indicator | NVTS | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 61.46 |
| Support Level | $8.01 | $5.59 |
| Resistance Level | $10.24 | $6.01 |
| Average True Range (ATR) | 0.66 | 0.19 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 20.60 | 83.52 |
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.